Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fastly Inc (FSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fastly Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Fastly Inc trades at $19.5 (market cap $3.07B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 13× Fastly Inc's market cap, and Fastly Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FSLY | |
|---|---|---|
Market Cap | $39.89B | $3.07B |
Sector | Health | Technology |
52-Week High | $491.22 | $33.50 |
52-Week Low | $278.09 | $6.36 |
Enterprise Value | $38.15B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Fastly (FSLY) trades at $19.59, down 3.64% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue growth accelerated to 20% year-over-year in Q1 2026, though the company remains unprofitable with a net margin of -19.5% in 2025. Analyst consensus is mixed with a $25.80 price target, while recent news highlights partnerships and AI-driven compute growth.
The outlook is cautiously optimistic: continued revenue expansion and margin improvement offer upside potential, but persistent losses and competitive pressures pose risks. Investors should weigh the stock's discounted valuation against execution challenges in a crowded edge cloud market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
